PTC Therapeutics Honored For Patient Advocacy Efforts By The Genetic Alliance

South Plainfield, NJ - PTC Therapeutics, Inc. (PTC) recently announced that the company was awarded the Art of Industry Partnership Award by the Genetic Alliance. Genetic Alliance presents the Art of Listening, Art of Advocacy, and Art of Industry Partnership Awards annually.

"The Art of Industry Partnership Award honors a for-profit company that models the benefits of creative partnerships between consumer advocates and industry in advancing understanding and treatment of genetic conditions," stated Sharon Terry, chief executive of the Genetic Alliance. "PTC Therapeutics has proven itself a leader in establishing productive, effective partnerships between government, advocacy organizations and physicians to advance drug development in areas of high unmet medical need; areas where few other pharmaceutical companies have been willing to focus. We are proud to acknowledge their leadership with this award."

PTC has established relationships and partnerships with several advocacy groups, including the Muscular Dystrophy Association, the Parent Project Muscular Dystrophy, the Cystic Fibrosis Foundation, the Spinal Muscular Atrophy Foundation, and Fight SMA. Collectively these groups have provided significant funding to support research in multiple genetic disorders. Importantly, the advocacy community has also been essential in helping establishing clinical endpoints and facilitating better understanding the challenges and needs of those affected by genetic disorders. The result of this support is that PTC now has established one of the broadest genetic disorders pipelines in the industry with over eleven programs addressing Duchenne muscular dystrophy, cystic fibrosis, and spinal muscular atrophy.

"We are honored to receive this award from the Genetic Alliance. Our relationships with the advocacy community have been essential in our quest to develop innovative therapeutics in genetic disorders," stated Stuart W. Peltz, Ph.D., president and chief executive officer of PTC Therapeutics. "We look forward to continuing these valuable and productive collaborations with advocacy groups as well as the broader patient community."

SOURCE: PTC Therapeutics, Inc.